Caitong International Asset Management’s Climb Bio CLYM Stock Holding History

Caitong International Asset Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.6K	Buy	+886	New	+$9.15K	﹤0.01%	1127

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caitong International Asset Management's CLYM Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Climb Bio (CLYM) in Q2 2026: 886 shares worth $11.6K. The stake represents ﹤0.01% of the portfolio and ranks #1127 among its holdings.

109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Caitong International Asset Management held 886 shares of Climb Bio worth $11.6K as of Q2 2026.
Climb Bio was a new Caitong International Asset Management position in Q2 2026.
Climb Bio made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1127 holding.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.